BioAtla, Inc.
Company Information
Industry Biological Products, (No Diagnostic Substances)
SIC Code 2836
Entity Type operating
SEC Category Non-accelerated filerSmaller reporting company
State of Incorporation DE
Business Address 11085 TORREYANA ROAD, SAN DIEGO, CA, 92121
Mailing Address 11085 TORREYANA ROAD, SAN DIEGO, CA, 92121
Phone 858-558-0708
Fiscal Year End 1231
EIN 851922320
Financial Overview
FY2025
$14.27M
Stockholders' Equity
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| 10-K Annual financial report | March 31, 2026 | View on SEC |
| 8-K Current report of material events | March 31, 2026 | View on SEC |
| 8-K Current report of material events | March 23, 2026 | View on SEC |
| 424B2 Prospectus for shelf offering | March 20, 2026 | View on SEC |
| 424B2 Prospectus for shelf offering | March 13, 2026 | View on SEC |
| 4 Insider stock transaction report | March 12, 2026 | View on SEC |
| 4 Insider stock transaction report | March 12, 2026 | View on SEC |
| 4 Insider stock transaction report | March 12, 2026 | View on SEC |
| 424B2 Prospectus for shelf offering | March 9, 2026 | View on SEC |
| 8-K Current report of material events | March 2, 2026 | View on SEC |
Annual Reports
10-K March 31, 2026
- Exploring strategic alternatives including a potential company or asset sale
- Proprietary 'Conditionally Active Biologics' (CABs) technology platform
Material Events
8-K Financial Distress March 31, 2026
High Impact
- Active exploration of strategic alternatives including sale or merger
- Proprietary 'Conditionally Active Biologic' (CAB) platform available for acquisition
8-K Financial Distress March 23, 2026
High Impact
- Developing new, targeted cancer drugs using special CAB technology, aiming for better efficacy and fewer side effects.
- Company is taking strong, needed steps to stabilize its stock price and motivate leaders to secure crucial funding.
8-K Financial Distress February 9, 2026
High Impact
- BioAtla (BCAB) secured a temporary stay, allowing its stock to continue trading on Nasdaq despite a delisting notice.
- The company is actively appealing Nasdaq's delisting decision, challenging rule interpretations and alleged policy changes.
8-K Financial Distress February 6, 2026
High Impact
- Nasdaq will suspend trading of BioAtla, Inc.'s common stock due to non-compliance.
- The delisting is primarily due to failure to meet the minimum bid price ($1.00) and stockholders' equity ($2.5 million) requirements.
8-K Financial Distress December 30, 2025
High Impact
- BioAtla shareholders approved a plan to issue new stock for financing purposes.
- Shareholders did not approve a proposal for a reverse stock split.
Related Companies
Companies in the same industry (SIC: 2836)
Kodiak Sciences Inc.
KOD Biological Products, (No Diagnostic Substances)
BRAINSTORM CELL THERAPEUTICS INC.
BCLI Biological Products, (No Diagnostic Substances)
Alvotech
ALVO Biological Products, (No Diagnostic Substances)
Liminatus Pharma, Inc.
LIMN Biological Products, (No Diagnostic Substances)
Green Planet Bio Engineering Co. Ltd.
GPLB Biological Products, (No Diagnostic Substances)
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.